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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease, causing rapid 
degeneration in motor function. About 10% of  the cases are familial (1), including genetic causes such as 
hexanucleotide expansion repeats in c9orf72 (2, 3), mutations in DNA- and RNA-binding proteins like 
TDP-43 (4, 5) and FUS (6, 7), as well as the most well-studied inherited cause, that of  superoxide dismutase 
1 (SOD1), which represents 20% of  all familial cases in some populations (SOD1 ALS cases) (8, 9). A com-
mon feature of  ALS is misfolding or aggregation of  polypeptides or proteins that deposit in motor neurons 
and may indeed be the root cause of  cell toxicity. There have been approximately 150 genetic mutations 
identified in SOD1 that cause ALS, varying in their rates of  disease progression and severity and partially 
correlating with the degree of  misfolding or aggregation (10).
Unlike the majority of ALS cases in which the cause of disease is unknown, genetic forms, such as those 
associated with SOD1, provide a clearer target for therapeutic intervention. Recently targeted strategies for 
diseased protein in neurodegenerative disease have led to several drug technologies that are currently being test-
ed in ALS (11). These include antisense oligonucleotide (ASO) therapy and viral-delivered siRNA strategies, 
shown to be successful in reducing SOD1 and delaying disease progression in animal models and currently 
being evaluated in clinical trials (12–15). Another therapeutic approach is the use of the drug Arimoclomol, an 
The discovery of novel biomarkers has emerged as a critical need for therapeutic development 
in amyotrophic lateral sclerosis (ALS). For some subsets of ALS, such as the genetic superoxide 
dismutase 1 (SOD1) form, exciting new treatment strategies, such as antisense oligonucleotide–
mediated (ASO-mediated) SOD1 silencing, are being tested in clinical trials, so the identification 
of pharmacodynamic biomarkers for therapeutic monitoring is essential. We identify increased 
levels of a 7–amino acid endogenous peptide of SOD1 in cerebrospinal fluid (CSF) of human SOD1 
mutation carriers but not in other neurological cases or nondiseased controls. Levels of peptide 
elevation vary based on the specific SOD1 mutation (ranging from 1.1-fold greater than control in 
D90A to nearly 30-fold greater in V148G) and correlate with previously published measurements 
of SOD1 stability. Using a mass spectrometry–based method (liquid chromatography–mass 
spectrometry), we quantified peptides in both extracellular samples (CSF) and intracellular 
samples (spinal cord from rat) to demonstrate that the peptide distinguishes mutation-specific 
differences in intracellular SOD1 degradation. Furthermore, 80% and 63% reductions of the 
peptide were measured in SOD1G93A and SOD1H46R rat CSF samples, respectively, following treatment 
with ASO, with an improved correlation to mRNA levels in spinal cords compared with the 
ELISA measuring intact SOD1 protein. These data demonstrate the potential of this peptide as a 
pharmacodynamic biomarker.
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activator of heat shock proteins (HSPs) that facilitate increased protein folding and stabilization in response to 
cell damage and stress, previously shown to be diminished in mouse models of ALS (16, 17). Arimoclomol has 
shown promising neuroprotective properties in experiments with mice and is currently being tested in clinical 
trials (17–20). In addition to establishing improved treatments for SOD1 ALS, it will be valuable to find phar-
macodynamic markers that are useful for evaluating the various treatment strategies under investigation. One 
such validated assay involves measuring SOD1 protein in CSF, shown to decrease approximately 40% upon 
treatment with ASOs in SOD1G93A rats (21). There is no current assay, though, that can distinguish differences 
in stability of SOD1, which can lead to protein misfolding, a critical component of the disease and potentially 
an important marker for current therapeutic strategies.
We investigated biomarkers in ALS using untargeted metabolomic analysis of  cerebrospinal fluid 
(CSF), initially in established ALS rat models expressing mutant SOD1 proteins with markedly different 
biochemical characteristics, including dismutase-active SOD1G93A and -inactive SOD1H46R (22). Increased 
levels (~10-fold) of  an endogenous peptide of  SOD1 were discovered and further tested in human CSF of  
SOD1 mutation carriers and controls using a quantitative assay developed for this peptide. We observed 
varying degrees of  peptide elevation that reflect mutation-specific differences in SOD1 stability and break-
down. We also demonstrate using ASO-treated rats the peptide’s potential utility as a pharmacodynamic 
biomarker for SOD1-targeted drugs.
Peptides have previously been shown to be elevated in other neurological disorders, such as Alzheimer’s 
disease, specifically tau and a fragment of amyloid-β protein (23), but no studies to our knowledge have investi-
gated small endogenous peptide products from intracellular protein turnover mechanisms (e.g., proteasome or 
autophagy) as a monitor for aberrant protein misfolding and processing in disease states. We believe the assay 
described here can assess these properties for SOD1 mutation carriers, relevant for both improved understanding 
of the role of SOD1 in disease, as well as for SOD1-targeted therapies currently under investigation.
Results
Biomarker discovery in SOD1 rats using liquid chromatography–mass spectrometry. Our initial search for biomarkers 
in ALS was performed with CSF samples from the mutant SOD1G93A rat model (n = 9) and age-matched ani-
mals expressing human SOD1WT using a previously validated metabolomics platform (24). Although there were 
small changes in a handful of metabolites, a nearly 10-fold change in 2 analytes (m/z of 351.195 and 307.681) 
that eluted approximately 0.2 minutes from each other was detected (Figure 1A). We measured a similar ele-
vation in a second mutant SOD1 rat model (SOD1H46R, n = 4 rats), whose expression of dismutase-inactive, 
SOD1-mutant protein causes age-dependent paralytic disease (Figure 1B). Analysis of the charge state, chro-
matographic elution time, and tandem mass spectrometry (MS/MS) patterns suggested that these compounds 
were peptides. The former peptide 351 m/z had a greater, more reliable overall signal, and so we proceeded 
with absolute identification of this peptide, whose sequence was found to be SDGPVKV by matching both the 
fragmentation pattern (MS/MS) and chromatographic elution profile with that of a custom-synthesized peptide 
(Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.122768DS1). From these data, we also identified the sequence of the 308 m/z ion to be DGPVKV, which 
is the sequence of peptide 351 m/z missing the N-terminal serine (Supplemental Figure 2).
The matched sequences were searched against both rat and human genomic databases using the 
protein BLAST search tool (National Center for Biotechnology Information). The only feasible match 
for the larger peptide was the sequence SNGPVKV from human SOD1, with a single D>N substitution, 
a common occurrence in proteins because of  N deamidation. The D form carries a mass difference of  
1.007 amu, so it could not be misconstrued with the N form using our high-resolution mass spectrome-
try. We used a synthesized N version of  the peptide to ensure there was no preparative- or instrument-in-
duced deamidation (Supplemental Figure 1D).
In addition to elevations in CSF, we observed increased intracellular accumulation of  the endogenous 
peptide in total spinal cord homogenates from SOD1G93A compared with SOD1WT rats (Figure 1C). It is 
also important to note that this increase was not caused by elevation of  intact SOD1 protein in spinal cords, 
which we show was similar in SOD1G93A and even diminished in SOD1H46R (Figure 1D), thus suggesting a 
unique or increased intracellular SOD1 turnover process occurring in the SOD1 mutants.
Translation of  biomarker measurement to human CSF samples. We measured the same 351 m/z peptide 
in human CSF, but the 308 m/z peptide was not detected. We therefore focused on the 351 m/z pep-
tide in further studies (termed “SOD1 peptide” in this manuscript) and measured its concentration in 27 
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human CSF samples from SOD1 mutation carriers (n = 14 ALS patients, and n = 13 presymptomatic gene 
mutation carriers), 29 controls (with no known neurological disease), and 30 neurological disease controls 
(Alzheimer’s disease and multiple sclerosis) using a liquid chromatography–mass spectrometry (LC-MS/
MS) method developed for absolute quantification (i.e., standard curve generated for each batch and stable 
isotope dilution for internal standard use). The mass spectrometry analysis of  all mutation carriers and 
control samples was executed by an observer who was blinded to the sample identity. All SOD1 variants 
were elevated compared with both control and disease controls, ranging from only 1.1-fold in D90A to 
as much as 30-fold for V148G (Figure 2 and Table 1). A4V, the most common SOD1 variant in North 
America, had 5 unique patient samples measured, with a 9-fold elevation from controls, with only a 16% 
SD within the cohort (224.6 ± 43.0 picomolars [pM]). The lone A4T sample had nearly identical peptide 
levels as the A4V samples. It is interesting to note that the only recessive form, D90A, exhibited the least 
amount of  peptide, and the A89V mutation, which exhibits incomplete penetrance, was also on the lower 
end of  the fold elevation among the variants measured. The 2 A89V samples tested were acquired from 
the same patient but 4.1 years apart. V148G, an aggressive variant (2.1 years average disease duration; ref. 
10), showed the highest levels (755.0 ± 137.2 pM) of  peptide, which were measured in presymptomatic 
mutation carriers. Notably, a third V148G sample was analyzed from an ALS patient treated with Arimo-
clomol as part of  a clinical trial, and the result was a considerably lower peptide concentration (250.0 pM). 
Overall, although the range of  the SOD1 peptide concentrations varied extensively among the different 
SOD1 variants, the increased concentration was mostly specific to the SOD1 ALS mutation, exhibiting a 
low intracohort deviation (<20% SD) for the 5 out of  7 mutations for which multiple patient samples could 
Figure 1. Discovery of elevated peptides in CSF of SOD1 rats. (A) Volcano plot from untargeted metabolomics analysis comparing SOD1G93A rats with SOD1WT 
rats. Two analytes (shown in magenta) were significantly elevated, approximately 12-fold (P < 0.0001), and later identified as peptides of SOD1. (B) Dot plots 
comparing integrated peak areas of analyte 351.195 m/z from LC-MS/MS runs of SOD1G93A (n = 9) and SOD1H46R (n = 4) with SOD1WT (n = 12) rats (12-fold and 
10-fold change compared with WT respectively; P < 0.0001 from Mann-Whitney U test). (C) SOD1 peptide (m/z 351.195) concentration determined in spinal 
cord homogenates (WT: n = 3; G93A: n = 4; fold change: 5.5; P < 0.05). (D) Immunoblot analysis, showing intact SOD1 levels in spinal cords of symptomatic 
SOD1G93A, symptomatic SOD1H46R, and age-matched SOD1WT rats.
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be tested. The accuracy of  this marker in distinguishing carriers of  SOD1-linked mutations to both control 
and disease control cohorts was assessed using a ROC curve (Figure 2C). The assay has high overall spec-
ificity and sensitivity for ALS-associated SOD1 mutations (sensitivity of  92.6% at 80% specificity in both 
comparisons, area under the curve of  0.96 for SOD1 analyzed against control and 0.95 against diseased 
control, 95% confidence interval of  0.89–1.01, P < 0.0001).
Tracing the origin of  the endogenous peptide. An important aspect to assess was whether deamidation was 
occurring in the native protein state and whether it was greater in mutant SOD1 than WT. Deamidation of  
native protein often occurs in aged protein but can also be more abundant in regions of proteins that are more 
dynamic (lower order of structure) or misfolded (25). We investigated native SOD1 protein deamidation at the 
same amino acid position (ASN 26) from spinal cords of SOD1G93A rats and compared these to control human 
SOD1WT rats. No difference in percentage of deamidation of native SOD1 was observed between SOD1WT and 
SOD1G93A homogenates, observed at levels of less than 10% for both groups (Supplemental Figure 3). This result 
demonstrated that the cleaved peptide product is therefore deamidated primarily after proteolysis, rather than in 
the intact protein state. Our findings of postproteolytic deamidation are in agreement with research highlighting 
that asparagines in unfolded proteins or peptides undergo significant deamidation endogenously (26), especially 
those that neighbor a glycine residue as is the case in the SOD1 peptide we identified.
We used an in silico prediction tool (NetChop20S-3.0; ref. 27) to determine the likelihood of this peptide 
resulting from ubiquitin-based proteasomal cleavage. The 20S proteasome has previously been linked to mutant 
SOD1 degradation in ALS (28). The analysis, using predictive 20S proteasomal degradation of the SOD1 protein 
Figure 2. SOD1 peptide in human CSF samples. (A) Comparison between 29 control samples, 30 disease control 
samples, and 27 SOD1 samples. There was a 9-fold difference (Mann-Whitney U test, P < 0.0001) between the SOD1 
group and both control groups (scatter plot showing bars for mean and SD). (B) Bar graphs of peptide concentrations 
for the different genetic variants of SOD1 (individual measurements represented as dots). The number of unique 
samples of a given variant is noted above the bar when 2 or greater, and error bars denote standard deviation. (C) 
Receiver operator characteristic (ROC) curve comparing SOD1 with control and disease control groups (area under the 
curve of 0.95 and 0.96, respectively).
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sequence, identified that the amino acid N-terminal to the peptide (E24), as well as the C-terminal residue of the 
peptide (V31), had high likelihoods of cleavage by the proteasome (scores > 0.8), whereas further internal frag-
ments of this peptide were considerably less probable (scores all < 0.5) (Supplemental Figure 4).
Because the rate of  protein turnover can be influenced by protein misfolding and decreased stability, we 
correlated our peptide concentrations to relevant SOD1 stability data in the literature. Lindberg et al. previ-
ously characterized SOD1 stability changes (ΔΔG kcal/mol) in common mutants of  ALS, considering both 
destabilization of  the free monomer, as well as the dimer interface (29). For the 8 overlapping mutants mon-
itored by both their study and ours, we observed a significant correlation between peptide concentration and 
SOD1 destabilization (ΔΔG) in relation to WT SOD1, as shown in Figure 3 (Spearman’s r: –0.75, P < 0.05).
SOD1 peptide as a pharmacodynamic marker. To determine whether the SOD1 peptide could represent a 
pharmacodynamic biomarker for SOD1-lowering therapies, presymptomatic SOD1G93A and SOD1H46R rats 
were treated with a single intraventricular bolus injection of  ASOs (14) targeting human SOD1 RNA or 
with saline. After 6 weeks of  treatment, SOD1 peptide was quantified in CSF from ASO-treated mutant 
SOD1 rats compared with CSF from saline-treated and untreated animals carrying the mutation (referred 
to as “non–ASO-treated”). An 80% decrease in the SOD1 peptide was measured in the CSF of  ASO-treat-
ed SOD1G93A as compared with non–ASO-treated rats (8178 ± 730 pM vs. 1661 ± 326 pM), while a 63% 
decrease was observed in ASO-treated SOD1H46R rats (3445 ± 1784 pM vs. 1279 ± 55 pM). Per condition, 
n = 4 rats were used (P < 0.05, Mann-Whitney U test for both comparisons) (Figure 4). Note that the levels 
of  SOD1 peptide measured in CSF from non–ASO-treated SOD1G93A rats were 2.4-fold higher than in 
the mutant SOD1H46R animals, possibly because of  the higher levels of  expression of  the human transgene 
(Figure 1D). We compared the decrease in peptide levels with mRNA levels measured in the spinal cord, 
as well as the standard SOD1 ELISA used as a pharmacodynamic marker in current ASO clinical trials 
(Figure 4 and Table 2). In SOD1G93A rats, we observed a 77% reduction in mRNA levels, very similar to 
the 80% reduction in peptide, while SOD1 protein as measured by ELISA was reduced by only 32%. For 
H46R, there was a similar percentage reduction in mean peptide levels as there was mRNA following ASO 
treatment (63% vs. 64%, respectively). The SOD1 ELISA for H46R was inconclusive and is not shown. We 
believe the antibody for the ELISA kit may not recognize the H46R-misfolded form of  SOD1 as well as it 
does G93A, and because the rat model expresses only the mutant form, unlike human patients, who are 
typically heterozygous, the assay may not be applicable for this mutation in rats.
Discussion
We believe that the peptide product of  intracellular SOD1 degradation described in this manuscript pro-
vides a simple and highly sensitive assay, using CSF, for assessing SOD1 protein stability and degradation 
in vivo. Because greater protein misfolding can lead to greater degradation (30, 31), we believe increased 
SOD1 peptide concentrations are correlated to the decreased stability of  SOD1, which varies with the 
severity of  the mutation. We observed a significant correlation to previously collected stability measure-
ments of  SOD1 mutants but did not observe a significant correlation with survival in our limited sampling, 
primarily because of  outliers, such as G41D and G85R, which had high peptide levels, yet are associated 
with higher survival times. Lindberg et al. also reported these specific genetic outliers in their correlation 
with survival, hypothesized as being related to changes in net charge, which may affect aggregation and 
disease progression differently than a neutral amino acid substitution (29).
Interestingly, the levels of  the SOD1 peptide measured in CSF were stable through disease course, 
with the increased fold change being similar at early and late stages of  disease in SOD1-mutant rats and 
in the genetic variant D90A, where we measured both presymptomatic and affected patient samples (from 
different individuals), with little difference observed (30 pM vs. 25 pM). In addition, the 2 measurements 
of  A89V CSF from the same patient staggered by nearly 4 years were nearly identical (80.9 pM vs. 81.3 
pM). Farr et al. previously reported that the turnover rate of  the soluble pool of  SOD1 was identical in 
presymptomatic and symptomatic mice (32), which if  it applies similarly in humans, could explain this lack 
of  change during disease progression.
The data show that the peptide increase is also found intracellularly in spinal cord tissue in addition 
to CSF, and in silico predictions implicate the 20S proteasome as a possible mechanism for this peptide 
product, though lysosomal degradation cannot be ruled out at this stage. Recognizing that we would not be 
able to measure actual turnover rates of  human SOD1 variants, which would require stable isotope admin-
istration into humans (33), we compared our SOD1 peptide levels from human CSF with turnover rates 
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previously described (28, 32, 33). Di Noto et al. measured proteasomal SOD1 degradation in vitro (using 
purified 20S proteasome) and showed an ascending rate of  turnover for 3 variants (G37R<G93A<A4V) 
(28). Interestingly, we found a similar order of  SOD1 peptide concentrations among these same 3 variants. 
To date, only 2 studies have quantified SOD1 turnover in vivo, one executed in mice and the other in rats 
(32, 33). Though strict comparisons of  the previous studies cannot be done, because different types of  
rodents and MS-based methodologies were used, it is worth noting that differences in turnover rate (G85R 
was 8.5 times faster than WT as measured by Farr et al., and G93A was 1.6 times faster than WT in 
Crisp et al.) followed a similar order as our SOD1 peptide concentrations (G85R>G93A, Table 1) (32, 33). 
Future experiments measuring both turnover rate and SOD1 peptide levels from the same subject for a vari-
ety of  mutations will be required to determine whether the peptide can be used as a surrogate for evaluating 
SOD1 turnover in the disease, a measurement that would be especially valuable for optimizing drug dosing 
and administration frequency for therapies such as ASOs.
We believe the major clinical application of  this LC-MS/MS–based peptide assay would in fact be for 
pharmacodynamic monitoring. The decreased levels of  the peptide in CSF upon SOD1 ASO treatment 
are indicative of  reduced SOD1 protein levels in the CNS of  the treated SOD1-mutant rats. The reduction 
also closely follows the reduction in SOD1 mRNA measured in spinal cord tissue, demonstrating its strong 
potential as a marker to serve in monitoring for target engagement in clinical trials using SOD1-targeted 
therapies. Based on comparisons with the ELISA for the SOD1G93A cohort, it also appeared that the peptide 
assay is a more sensitive option for pharmacodynamic monitoring in CSF. Though the pretreatment peptide 
levels may vary by mutation, we believe this is a pharmacodynamic marker that could be used for all SOD1 
ALS patients, as long as pretreatment and posttreatment levels are measured for each patient. In addition 
to ASO-based therapies, we believe the peptide assay may be applicable to other lines of  therapy that target 
SOD1. For example, though we could not perform a similar experiment in rats using Arimoclomol, a drug 
that coinduces HSPs that affect protein folding, a single patient carrying V148G treated with Arimoclomol 
did show a nearly 3-fold lower level of  the peptide concentration as compared with 2 presymptomatic (and 
untreated) V148G carriers (Table 1), suggesting a pharmacodynamic potential for SOD1-targeting drugs 
that affect misfolding and stability.
Altogether, we believe this finding demonstrates a new approach for stratifying differences in stability 
and degradation of  diseased proteins that have peptide products released into the extracellular fluid. This 
particular assay provides a highly sensitive snapshot of  differences in SOD1 processing, even when intracel-
lular levels of  full-length SOD1 protein remain indistinguishable. Such an approach may be well suited for 
targeting of  protein degradation products in other neurological disorders associated with protein misfold-
ing, such as α-synuclein peptide products in the affected subset of  Parkinson’s patients.
Methods
Human sample acquisition. All patient samples were obtained from previously collected CSF, stored in 1 of  
3 repositories: (a) NEALS, (b) Washington University in St. Louis, and (c) University of  Miami Clinical 
Research in ALS, from IRB-approved studies. Sample identities (mutation type or control) from reposi-
tories 2 and 3 were blinded before assay and data sharing. UCSD Biochemical Genetics laboratory was 
approved by UCSD IRB for analyzing previously collected samples.
Figure 3. Correlation of endogenous pep-
tide concentration with SOD1 stability (ΔΔG 
kcal/mol) data from Lindberg et al. Eight 
mutations and WT overlapped between our 
own study and the Lindberg et al. study, as 
labeled in the graph. Correlation analysis: 
Spearman’s r = –0.75; P < 0.05.
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Peptide identification. Regarding MS/MS, initial peptides of  interest were searched in silico for potential 
sequence matches using Protein Prospector software (UCSF). Two potential sequences matched nearly all 
experimental fragment ions, and these 2 along with 3 others with slightly worse overlap were custom-synthe-
sized for confirmation (GenScript Corp.). Each of  the 5 peptides was evaluated for chromatographic elution 
time, peak shape, and MS/MS fragmentation patterns and compared with the experimental peptide of  inter-
est. Two of  these had identical elution times as the compound of  interest, but only 1 of  these, SDGPVKV, 
exactly matched the chromatographic and fragmentation data (MS/MS), as shown in Supplemental Figure 1.
Peptide quantification. Following discovery of  the peptide marker from untargeted metabolomics platform 
(described in Supplemental Methods), 100 μl of  each CSF samples was extracted with 400 μl of  ice-cold meth-
anol containing 500 pM of a stable isotope version of  the peptide (containing 15N2/
13C6 lysine, synthesized by 
Sigma Aqua peptides). A 7-point standard curve (using 100 μl of  analyte-stripped serum as the blank matrix) 
was prepared with each batch, containing a range of  10 to 1000 pM of unlabeled peptide standard for the bulk 
of  data collection (an initial range of  100 to 5000 pM was used for the first batch), shown in Supplemental 
Figure 5. Following vortexing for 30 seconds and deproteinization, supernatants were removed and dried in 
a speed vac (integrated with a lyophilizer for cold drying; Thermo Fisher). The sample was resuspended in 40 
μl of  acetonitrile/0.1% formic acid (FA) (Honeywell). Half  of  the material was loaded as a 20-μl injection on 
a Waters Xbridge C18-BEH column (incubated at 30°C in column oven). API 4000 and API 4500 (AB Sciex) 
instruments were used for data collection and Multiquant software (AB Sciex) was used for quantitation cal-
culations. The MRM transition 351.2>499.3 was used for quantitation of  the endogenous peptide (collision 
energy [CE]: 16), while 351.2>246.2 (CE: 23) was used as a confirmatory transition. 355.2>507.30 was used 
for the isotopically labeled peptide standard. MRM transition 350.7>499.30 (CE: 17) was used to monitor 
potential nondeamidated peptide. Universal MS parameters used included DP: 70; EP: 10; CXP: 6.0; CAD: 
9.0; CUR: 40; IS voltage: 5500; GS1: 40; GS2: 70; and heating gas of  450°C. We used 100-ms dwell times 
for each transition (0.5-second total scan cycle time). Mobile phases included (a) 0.1% FA in water and (b) 
100% acetonitrile/0.1% FA. The following gradient steps were used for each 23-minute run: (a) 0- to 3-minute 
isocratic at 95%A, (b) 3–8 minutes (95%A to 50%A), (c) 8–8.1 minutes (50%A to 0%A), (d) 8.1- to 13-minute 
isocratic at 0%A, (e) 13–13.1 minutes (0%A to 95%A), and (f) 13.1- to 23-minute isocratic at 95%A. LC-MS/
MS–grade water was purchased from Honeywell.
Figure 4. Effects of SOD1-targeted ASO treatment on levels of mRNA, SOD1 peptide (LC-MS/MS), and SOD1 protein 
(ELISA). mRNA was measured in spinal cords of control and ASO-treated rats, while SOD1 peptide and protein assays 
were performed on CSF samples from the same rats. (A) Presymptomatic SOD1G93A rats (n = 4: 2 saline injected, 2 non-
injected) compared with ASO-treated littermates (n = 4). For the mRNA assay, LC-MS/MS assay, and ELISA, 77%, 80%, 
and 32% mean reductions were measured, respectively, following ASO treatment. (B) Presymptomatic SOD1H46R rats (n 
= 4: 2 saline injected, 2 noninjected) compared with ASO-treated littermates (n = 4) showing 64% and 63% reduction 
in mean mRNA and peptide levels, respectively. ELISA data for SOD1H46R were inconclusive as described in the Results 
section and are not shown. *P < 0.05 using Mann-Whitney U tests for all comparisons.
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Interbatch/instrument normalization. The first batch of quantitative analysis was performed on an API 4000 
triple quadrupole instrument with a standard curve range of 100 to 5000 pM, a range selected based on prelimi-
nary measurements. Though most of the SOD1-mutant samples fell well within this range, the control samples 
and 3 of the SOD1 samples were below the limit of quantitation. All future batches were run with an adjusted 
standard curve range (10–1000 pM) to cover the full range of peptide levels in controls and patients, also using 
a more sensitive instrument, the API 4500 (AB Sciex). Several of the control samples and SOD1 samples 
were rerun in these later batches to help normalize samples from the first batch that were below the levels of  
accurate quantitation. The majority of all samples, therefore, did not require any further normalization and are 
expressed in absolute concentrations fit to linear regressions of standard curves shown in Supplemental Figure 
5. Many of the samples from the first batch were not simply rerun on the newer platform because of a limited 
volume of sample that was required for repeat extraction/analysis. Quality controls (QCs) at different concen-
tration ranges were run in multiple batches, but a full bioanalytical validation using 4 consecutive days of repeat 
standard curve and QC analyses to determine intraday and interday precision and accuracy was not performed 
for this research study but will be done before use in any future clinical applications.
Immunoblot analysis. Transgenic rats expressing hSOD1G93A (34) and hSOD1H46R (35) were as originally 
described and maintained by standard protocols. All animal procedures were consistent with the require-
ments of  the Animal Care and Use Committees of  the University of  California. Spinal cords from non-Tg 
SOD1WT and symptomatic SOD1G93A or SOD1H46R rats were homogenized in cold PBS 1× supplemented 
with protease inhibitors. The lysates were centrifuged for 10 minutes at 1000 g, and the resulting superna-
tants (clarified tissue extracts) were analyzed by immunoblotting. Equal protein amounts were separated 
on SDS-PAGE, transferred to nitrocellulose membranes, and probed with the polyclonal anti-SOD1 (Enzo 
Life Sciences, ADI-SOD-100, diluted at 1:1000) or monoclonal anti-GAPDH antibodies (Abcam, clone 
6C5, ab8245, 1:10,000) followed by horseradish peroxidase–conjugated secondary antibodies (Jackson 
ImmunoResearch). Pico ECL (Pierce) was used to detect immunoreactive bands.
Rat sample acquisition and injection of  ASO. CSF from rats at early symptomatic stages was acquired 
for metabolomics and ASO experiments as previously described (36). Spinal cords used for native SOD1 
deamidation quantitation were obtained following euthanasia as described previously (22).
Table 1. Study participant characteristics and peptide concentrations
Mutation Group Sex (no. F/
no. M)






(pM) (mean ± SD)
V148G 2 presymptomatic 2/0 54 (n/a) 755.0 ± 137.2
V148G 1 symptomatic, treatedA 0/1 (n/s) 2.5 250.0
G41D 2 presymptomatic 1/1 (n/s) (n/a) 447.0 ± 59.4
G85R 2 symptomatic 0/2 57 1.7 302.5 ± 152.0
A4T 2 symptomatic 0/1 (n/s) 1.0 270.0
A4V 5 symptomatic 2/3 48 1.1 224.6 ± 43.0
L144F 3 presymptomatic 1/2 55 (n/a) 160.3 ± 28.0
I113T 5 presymptomatic 5/0 43 (n/a) 148.2 ± 59.8
G93A 1 symptomatic 1/0 (n/s) 1.3 147.0
A89V 1 symptomatic,  
2 collections
0/1 (n/s) 5.3 81.1 ± 0.3
G93S 1 symptomatic 0/1 (n/s) 10.0 30.7
D90A 1 presymptomatic/1 
symptomatic
1/1 60 0.7B 27.2 ± 3.6
G37R 1 symptomatic 1/0 (n/s) (n/a) 25.2
Disease controls 30 neuro. diseaseC – – – 25.8 ± 2.8
Controls 29 healthy controlsC – – – 24.3 ± 4.8
CSF samples were acquired from 3 repositories: Northeastern ALS Consortium (NEALS), Washington University in St. 
Louis, and University of Miami. For genetic variants that had only 1 sample, to maximize participant anonymity, no age 
or sex is displayed. ASample collected after participant was treated with Arimoclomol as part of a clinical trial. BFor the 
symptomatic participant only. CSex and age information not available for the control cohorts. (n/a), not applicable (if 
presymptomatic) or not available (if symptomatic); (n/s), not shown.
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Intracerebroventricular stereotactic injections of  20 μl of  ASO solution, corresponding to a total of  
1000 μg of  ASO (Ionis Pharmaceuticals), were administered using the following coordinates: –1.4 mm 
M/L, –0.4 mm A/P, and –3.5 mm D/V from the bregma. Presymptomatic (2-month-old SOD1G93A and 
4-month-old SOD1H46R) rats were treated with either PBS 1× or ASO targeting the human SOD1 sequence 
(TTAATGTTTATCAGGAT). After 6 weeks of  treatment, CSF was collected. In brief, after anesthesia 
(ketamine/xylazine or propoflo injection), a blunt dissection was made through the musculature down to 
the atlanto-occipital membrane, between the caudal part of  the cerebellum and medulla oblongata, to gain 
access through to the cisterna magna. CSF was sampled out via 25-gauge needle/syringe aspiration. About 
100 μl was collected per rat and directly snap-frozen into liquid nitrogen.
mRNA measurement in rat spinal cord from ASO experiment. Levels of  hSOD1 mRNA and GAPDH 
were measured from frozen, powderized spinal cords as performed previously (37). Primer sequenc-
es for hSOD1 and rat GAPDH were as follows: hSOD1, forward, TGCATCATTGGCCGCA; reverse, 
TTTCTTCATTTCCACCTTTGCC; and probe, ACTGGTGGTCCATGAAAAAGCAGATGACTT; 
GAPDH, forward, TGTTCTAGAGACAGCCGCATCTT; reverse, CACCGACCTTCACCATCTTGT; 
probe, TTGTGCAGTGCCAGCCTCGTCTCA.
Proteomics experiments are detailed in the Supplemental Methods.
Statistics. Markerview software (AB Sciex) was used for untargeted metabolomics data processing and ini-
tial statistical analysis. All further statistical analyses (U tests, box plots, Spearman’s rank correlation analysis, 
and ROC curves) were performed using GraphPad Prism v.7.01 software. D’Agostino-Pearson normality test 
was performed to evaluate peptide concentration distributions of  both control and SOD1 populations. The 
control group showed a normal distribution (P > 0.05) of  peptide concentrations, but the SOD1 group did 
not. Therefore, nonparametric analyses were used, including Mann-Whitney unpaired U tests for univariate 
testing (P < 0.05 considered significant, 2-tailed) and Spearman’s rank correlation analysis.
Peptide concentrations were correlated with previously published stability data of  SOD1 using Graph-
Pad Prism. The ΔΔG fit best to the log of  the peptide concentration in our analysis. We believe the basis for 
the scaling can be traced to the standard equation (ΔG = –RTlnK), which can be used to relate the change 
in protein stability upon unfolding (ΔGU) with the natural log of  the equilibrium constant Keq, composed 
of  the quotient Ku/Kf (unfolded/folded).
Study approval. All peptide assays using previously collected human CSF samples was approved by 
UCSD IRB (La Jolla, California, USA). Patient consent was not required as all samples were acquired 
from biorepositories previously approved for sharing samples for ALS biomarker studies. All rat experi-
ments were approved by UCSD IUCAC board (La Jolla, California, USA).
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